Annual Cash & Cash Equivalents
$333.73 M
+$76.50 M+29.74%
December 31, 2024
Summary
- As of March 12, 2025, PRCT annual cash & cash equivalents is $333.73 million, with the most recent change of +$76.50 million (+29.74%) on December 31, 2024.
- During the last 3 years, PRCT annual cash & cash equivalents has risen by +$29.41 million (+9.66%).
- PRCT annual cash & cash equivalents is now at all-time high.
Performance
PRCT Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$333.73 M
+$136.96 M+69.61%
December 31, 2024
Summary
- As of March 12, 2025, PRCT quarterly cash and cash equivalents is $333.73 million, with the most recent change of +$136.96 million (+69.61%) on December 31, 2024.
- Over the past year, PRCT quarterly cash and cash equivalents has increased by +$136.96 million (+69.61%).
- PRCT quarterly cash and cash equivalents is now at all-time high.
Performance
PRCT Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
PRCT Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +29.7% | +69.6% |
| 3 y3 years | +9.7% | +69.6% |
| 5 y5 years | +694.2% | +69.6% |
PRCT Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +50.4% | at high | +122.9% |
| 5 y | 5-year | at high | +694.2% | at high | +233.3% |
| alltime | all time | at high | +694.2% | at high | +233.3% |
PROCEPT BioRobotics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $333.73 M(+29.7%) | $333.73 M(+69.6%) |
| Sep 2024 | - | $196.76 M(-8.1%) |
| Jun 2024 | - | $214.09 M(-5.1%) |
| Mar 2024 | - | $225.58 M(-12.3%) |
| Dec 2023 | $257.22 M(+15.9%) | $257.22 M(-10.4%) |
| Sep 2023 | - | $287.09 M(+91.8%) |
| Jun 2023 | - | $149.69 M(-17.3%) |
| Mar 2023 | - | $180.97 M(-18.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2022 | $221.86 M(-27.1%) | $221.86 M(-11.0%) |
| Sep 2022 | - | $249.22 M(-7.6%) |
| Jun 2022 | - | $269.81 M(-5.1%) |
| Mar 2022 | - | $284.29 M(-6.6%) |
| Dec 2021 | $304.32 M(+203.9%) | $304.32 M(-5.0%) |
| Sep 2021 | - | $320.48 M(+101.3%) |
| Jun 2021 | - | $159.22 M(+59.0%) |
| Dec 2020 | $100.13 M(+138.3%) | $100.13 M |
| Dec 2019 | $42.02 M | - |
FAQ
- What is PROCEPT BioRobotics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for PROCEPT BioRobotics?
- What is PROCEPT BioRobotics annual cash & cash equivalents year-on-year change?
- What is PROCEPT BioRobotics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for PROCEPT BioRobotics?
- What is PROCEPT BioRobotics quarterly cash and cash equivalents year-on-year change?
What is PROCEPT BioRobotics annual cash & cash equivalents?
The current annual cash & cash equivalents of PRCT is $333.73 M
What is the all time high annual cash & cash equivalents for PROCEPT BioRobotics?
PROCEPT BioRobotics all-time high annual cash & cash equivalents is $333.73 M
What is PROCEPT BioRobotics annual cash & cash equivalents year-on-year change?
Over the past year, PRCT annual cash & cash equivalents has changed by +$76.50 M (+29.74%)
What is PROCEPT BioRobotics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of PRCT is $333.73 M
What is the all time high quarterly cash and cash equivalents for PROCEPT BioRobotics?
PROCEPT BioRobotics all-time high quarterly cash and cash equivalents is $333.73 M
What is PROCEPT BioRobotics quarterly cash and cash equivalents year-on-year change?
Over the past year, PRCT quarterly cash and cash equivalents has changed by +$136.96 M (+69.61%)